" class="no-js "lang="en-US"> Ankyra Appoints Stephen Gorgol as Chief Financial Officer
Friday, April 12, 2024

Ankyra Therapeutics Appoints Experienced Financial Executive Stephen Gorgol as Chief Financial Officer

Ankyra Therapeutics, a biotech company developing targeted immune-activating agents for the treatment of cancer, has announced the appointment of Stephen Gorgol as chief financial officer. Mr. Gorgol, a proven financial leader within the biotech industry, joins Ankyra from Replimune Inc., where he served as chief accounting officer.

“We are thrilled to welcome Steve to the Ankyra team at this pivotal point in our development as we prepare to transition our lead candidate, ANK-101, into the clinic,” said Howard L. Kaufman, M.D., president and chief executive officer of Ankyra. “Steve brings extensive financial and accounting biotech experience to the role, and his expertise will provide a valuable resource as we advance the company toward becoming a clinical-stage organization.”

“Ankyra has significant potential to transform cancer care for many patients in need, and I’m excited to join the company at this exciting time,” said Mr. Gorgol. He added, that “with our unique Anchored Immunotherapy Platform, we have the potential to deliver the beneficial aspects of cytokine therapeutics to patients, while avoiding the unwanted side effects. This platform, and our lead program, could offer tremendous value to both patients and our stakeholders, and I am pleased to partner with Howard and the team to advance them forward.”

Mr. Gorgol brings over 40 years of experience in financial-focused roles across several industries, including nearly 25 years in life sciences and biotechnology. Stephen joins Ankyra from Replimune, where he served as the chief accounting officer and was responsible for financial, accounting, tax and human resources functions, and played a key role in the company’s successful 2018 initial public offering. Before Replimune, he served as vice president, finance and administration at uniQure. Prior to that, he served as the chief financial officer for BioVex, and earlier, as chief financial officer of Vista Medical Technologies. Before entering the biotechnology industry, he held a number of controller-focused roles. Mr. Gorgol received his B.S. in accounting from Plymouth State College in New Hampshire.

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more